Diagnostyka

Lab diagnostics network · Clinical laboratory diagnostics

Overview

Poland's largest medical-laboratory diagnostics group; a major 2024 GPW IPO and the commercial backbone of Polish diagnostics.

What they do

Diagnostyka S.A. is the largest private medical-laboratory diagnostics group in Poland and the commercial backbone of Polish diagnostics. The Group runs a nationwide network reported at more than 1,100 blood-collection points, around 150 laboratories and roughly 19 imaging facilities, serving over 20 million patients a year and performing well over 140 million tests annually across clinical chemistry, microbiology, genetics, histopathology and imaging.

Lead program & status

Rather than a clinical asset, Diagnostyka's lead "program" is its integrated lab-testing network and B2B/B2C testing services. The company held a major IPO on the Warsaw Stock Exchange (GPW), debuting on 7 February 2025, with shares priced at the top of the range (PLN 105) and an offering valued at close to PLN 1.7 billion. The sale was of existing shares held by MidEuropa-controlled LX Beta, not new issuance. Reported 2024 results showed roughly 23.6% revenue growth and a recurring EBITDA margin near 26%, on an estimated ~49% share of the private diagnostics market (ahead of Alab at ~19%).

Why it matters

Diagnostyka's scale, density and 2025 listing make it the reference operator for Polish diagnostics and a consolidator of an otherwise fragmented market, with reach into both public and private healthcare.

FAQ

When did Diagnostyka list on the stock exchange?

Diagnostyka debuted on the Warsaw Stock Exchange (GPW) on 7 February 2025, after an IPO that priced shares at PLN 105 and valued the offering at close to PLN 1.7 billion.

How large is Diagnostyka?

It is Poland's largest private diagnostics group, with a network of 1,100+ collection points and around 150 laboratories, serving over 20 million patients and running 140+ million tests a year.

What market share does Diagnostyka hold?

Reports put its share of Poland's private medical-diagnostics market at roughly 49%, ahead of the second-placed operator, Alab, at around 19%.

Company website / source ↗ Open the interactive map →